BGB-900-2001-IIT: A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Sep 22, 2026 - P2 | N=98 | Active, not recruiting | Sponsor: Fudan University | Trial completion date: Jun 2024 ➔ Jun 2027 | Trial primary completion date: Jun 2024 ➔ Jun 2026
Trial completion date • Trial primary completion date • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR
|